<DOC>
	<DOCNO>NCT02115464</DOCNO>
	<brief_summary>ALMERA randomize , phase II , open label study patient locally advance non-small cell lung cancer ( NSCLC ) compare standard radiotherapy plus concurrent chemotherapy without consolidation versus treatment plus concurrent Metformin continue 12 month . Metformin well tolerate inexpensive drug potential improve cancer patient outcome .</brief_summary>
	<brief_title>Advanced Lung Cancer Treatment With Metformin Chemo-Radiotherapy</brief_title>
	<detailed_description>This randomize , phase II , open label study patient locally advance NSCLC compare standard RT ( 60-63 Gy 6 week ) plus concurrent Cisplatin-based chemotherapy ( CRT ) without consolidation ( standard arm ) v CRT without consolidation plus treatment Metformin concurrent CRT continue total 12 month ( experimental arm ) . Ninety-four eligible consenting patient randomize one two treatment arm . Patients randomize experimental arm receive Metformin ( 2000 mg/day ) period 12 month . Patients continuously evaluate toxicity , assessed weekly clinic visit concurrent CRT treatment without consolidation follow clinic visit 3 , 6 , 9 12 month ( date randomization ) . Disease progression evaluate every 3 month 12 month . All patient follow 24 month ( 2 year ) survival . The primary objective study determine effect Metformin proportion patient free disease progression 12 month initiation drug treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Age &gt; /=18 &lt; /= 80 year age . 2 . Unresected pathologically ( histologic ) proven Stage 3a Stage 3b NSCLC adenocarcinoma , squamous cell , large cell mixed histology , diagnose within three month study randomization . 3 . Nonmetastatic disease stag : CTchest upper abdomen , brain MRI contrastenhanced CT within 12 week physical examination whole body FDGPET/CT scan within 8 week prior study randomization . 1 . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 . 2 . More 10 % weight loss past 3 month . 3 . Diabetic patient anyone currently take Metformin , insulin antihyperglycemic therapy . 4 . Pulmonary Function Test ( PFTs ) ( within last 12 week ) Forced Expiratory Volume ( FEV ) 1 &lt; 1.2 litre per second le 50 % predict . 5 . Complete Blood Count ( CBC ) biochemical renal liver function profile permit chemotherapy treatment ( per institutional standard care ) . 6 . Fasting blood sugar level &gt; /= 7.0 mmol per litre ( within last 12 week ) . 7 . Prior systemic chemotherapy lung cancer . 8 . Prior radiotherapy would overlap plan treatment area . 9 . Prior invasive malignancy within past 3 year ( except nonmelanomatous skin cancer noninvasive carcinoma insitu breast , oral cavity cervix ) . 10 . Known Acquired Immune Deficiency Syndrome ( AIDS ) . 11 . Patients increase risk lactic acidosis : severe congestive heart failure ( NYHA : class III IV ) , history metabolic acidosis , alcoholic intake &gt; 3 drink daily , severe liver disease , renal failure 12 . Known hypersensitivity allergy Metformin . 13 . Known pregnancy lactate female patient . 14 . Geographic inaccessibility followup . 15 . Inability provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Chemo-radiotherapy</keyword>
	<keyword>Lung cancer treatment</keyword>
</DOC>